JAK Inhibitor Screening — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Full blood count, liver and renal profile, lipids, hepatitis and TB screening
Baseline JAK-inhibitor assessment includes haematology, hepatic and renal function, lipid status, viral hepatitis and latent-tuberculosis screening, together with infection, vaccination, malignancy, cardiovascular and thromboembolic risk review.
Reference: UK Rinvoq summary of product characteristics (Current UK SmPC, accessed 30 July 2026): https://www.medicines.org.uk/emc/product/13935/smpc; MHRA: JAK inhibitors — measures to reduce cardiovascular, malignancy, VTE, infection and mortality risks (Published April 2023): https://www.gov.uk/drug-safety-update/janus-kinase-jak-inhibitors-new-measures-to-reduce-risks-of-major-cardiovascular-events-malignancy-venous-thromboembolism-serious-infections-and-increased-mortality